<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03833024</url>
  </required_header>
  <id_info>
    <org_study_id>332593-S1</org_study_id>
    <nct_id>NCT03833024</nct_id>
  </id_info>
  <brief_title>The MUFFIN-PTS Trial</brief_title>
  <acronym>MUFFIN-PTS</acronym>
  <official_title>The MUFFIN-PTS Trial: Micronized Purified Flavonoid Fraction for the Treatment of Post-Thrombotic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sir Mortimer B. Davis - Jewish General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sir Mortimer B. Davis - Jewish General Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this randomized controlled trial (RCT), the investigators will determine whether a 6-month
      course of oral Micronized Purified Flavonoid Fraction (MPFF 1000 mg daily), compared with
      placebo, improves the symptoms and signs of the post-thrombotic syndrome (PTS) and quality of
      life (QOL) at 6 months follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The post thrombotic syndrome (PTS) is a form of secondary chronic venous insufficiency (CVI)
      that develops after a deep vein thrombosis (DVT). It affects up to 50% of patients after a
      proximal DVT (i.e. DVT involving popliteal vein or more proximal veins), and 5-10% of
      patients develop severe PTS. PTS is a chronic condition that reduces quality of life (QOL)
      and for which no curative treatment is available. Cornerstones of PTS treatment include the
      use of elastic compression stockings (ECS) to reduce leg symptoms and prevent PTS
      progression. However, ECS are incompletely effective, burdensome and costly to patients.
      Micronized Purified Flavonoid Fraction (MPFF, Venixxa), a venoactive drug, has been reported
      to be effective in reducing venous symptoms and signs and improving QOL in patients with CVI
      and has the potential to be effective for the treatment of PTS. Further, use of Venixxa is
      safe, with only few very mild and reversible reported side effects. However, studies of MPFF
      in patients with CVI have been of low to moderate quality, and there has been little use of
      this drug in North America. In addition, the effectiveness of MPFF has never been
      specifically evaluated in patients with PTS. Given that the pathophysiological mechanism of
      PTS is complex and unique (combination of obstructive and reflux mechanisms as well as
      inflammation), it is uncertain if MPFF is effective in patients with PTS, even if it may be
      effective for CVI more generally.

      The MUFFIN-PTS study will be a multicentre (8-10 centres), randomized, placebo-controlled
      trial. Patients will be randomized (1:1 with stratification by centre) to receive 1000 mg of
      oral MPFF (Venixxa, one 500mg tablet BID) or an identically appearing placebo (one tablet
      BID) for 6 months, in addition to their usual PTS and DVT treatment (i.e. ECS and/or
      anticoagulation, at their treating physician's discretion). Its objectives are to evaluate
      the effectiveness and safety of MPFF (Venixxa) compared to placebo for the treatment of PTS.

      86 patients with lower limb PTS will be enrolled in the study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multicentre, randomized, placebo-controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind placebo-controlled trial with oral placebo</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in PTS</measure>
    <time_frame>6 months</time_frame>
    <description>Improvement will be defined as a decrease of at least 30% in the Villalta score or a Villalta score &lt;5 in the PTS-affected leg.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity of PTS</measure>
    <time_frame>baseline, 3, 6 and 9 months</time_frame>
    <description>Villalta score category (mild, moderate, severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in PTS</measure>
    <time_frame>3 and 9 months</time_frame>
    <description>Improvement will be defined as a decrease of at least 30% in the Villalta score or a Villalta score &lt;5 in the PTS-affected leg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous specific Quality of life</measure>
    <time_frame>3, 6 and 9 months</time_frame>
    <description>Venous-disease specific (VEINES-QOL) score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>General Quality of life</measure>
    <time_frame>3, 6 and 9 months</time_frame>
    <description>Generic QOL (EQ-5D-5L) score. The EQ-5D-5L consists of the EQ-5D-5L descriptive system and the EQ Visual Analogue scale (EQ VAS). The descriptive system comprises 5 dimensions (mobility, self care, usual activities, pain/discomfort, anxiety/depression). Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. This decision results in a 1-digit number expressing the level selected for that dimension. The digits for 5 dimensions can be combined in a 5-digit number describing the respondent's health state.
The EQ VAS records the respondent's self-rated health on a 20 cm vertical, visual analogue scale with endpoints labelled 'the best health you can imagine' and 'the worst health you can imagine'. This information can be used as a quantitative measure of health as judged by the individual respondents.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious Adverse Events (SAE)</measure>
    <time_frame>9 months</time_frame>
    <description>Includes drug-related SAE, DVT, Pulmonary Embolism (PE), death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient compliance with treatment</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Judged satisfactory if at least 80% of the study drug was reportedly taken</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' overall satisfaction with treatment</measure>
    <time_frame>3 and 6 months</time_frame>
    <description>Assessed with a 5-point Likert visual analog scale questionnaire (1 indicate patient is very satisfied with treatment and 5 that he is very unsatisified)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Villalta score</measure>
    <time_frame>3, 6, 9 months</time_frame>
    <description>Villalta score assessed as a continuous variable (greater score indicates more severe disease, score range 0 to 33)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>3, 6, 9 months</time_frame>
    <description>Analyzed as individual component of Villalta score (0 absent to 3 severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cramps</measure>
    <time_frame>3, 6, 9 months</time_frame>
    <description>Analyzed as individual component of Villalta score (0 absent to 3 severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Heaviness</measure>
    <time_frame>3, 6, 9 months</time_frame>
    <description>Analyzed as individual component of Villalta score (0 absent to 3 severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Paresthesia</measure>
    <time_frame>3, 6, 9 months</time_frame>
    <description>Analyzed as individual component of Villalta score (0 absent to 3 severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pruritus</measure>
    <time_frame>3, 6, 9 months</time_frame>
    <description>Analyzed as individual component of Villalta score (0 absent to 3 severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-tibial edema</measure>
    <time_frame>3, 6, 9 months</time_frame>
    <description>Analyzed as individual component of Villalta score (0 absent to 3 severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperpigmentation</measure>
    <time_frame>3, 6, 9 months</time_frame>
    <description>Analyzed as individual component of Villalta score (0 absent to 3 severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Redness</measure>
    <time_frame>3, 6, 9 months</time_frame>
    <description>Analyzed as individual component of Villalta score (0 absent to 3 severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin induration</measure>
    <time_frame>3, 6, 9 months</time_frame>
    <description>Analyzed as individual component of Villalta score (0 absent to 3 severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous ectasia</measure>
    <time_frame>3, 6, 9 months</time_frame>
    <description>Analyzed as individual component of Villalta score (0 absent to 3 severe)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Venous Ulcer</measure>
    <time_frame>3, 6, 9 months</time_frame>
    <description>Analyzed as individual component of Villalta score (0 absent or 1 present)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">86</enrollment>
  <condition>Post-Thrombotic Syndrome</condition>
  <arm_group>
    <arm_group_label>Venixxa</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Micronized Purified Flavonoid Fraction (MPFF) for 6 months MPFF 500 mg, BID (morning and evening) for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo for 6 months
1 Tablet, BID (morning and evening) for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micronized Purified Flavonoid Fraction</intervention_name>
    <description>After randomization (1:1 with stratification by centre) patients will receive 1000 mg of oral MPFF (Venixxa, one 500mg tablet BID) for 6 months, in addition to their usual PTS and DVT treatment</description>
    <arm_group_label>Venixxa</arm_group_label>
    <other_name>Venixxa group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>After randomization (1:1 with stratification by centre) patients will receive an oral placebo (one tablet BID) for 6 months, in addition to their usual PTS and DVT treatment</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Villalta score &gt;4 with at least two of the following four PTS manifestations (daily
             heaviness, cramps, pain, and objective edema) in the leg ipsilateral to a previous
             objectively diagnosed DVT, or DVT of unknown date but with presence of residual
             proximal or distal venous obstruction on ultrasound

        Exclusion Criteria:

          -  Recent acute ipsilateral DVT (&lt;3 months)

          -  Active ipsilateral venous ulcer

          -  Acute or chronic altered mental status

          -  Any venoactive drug intake within 3 months of the start of the study

          -  Allergy or hypersensitivity to MPFF/Venixxa

          -  Age&lt;18 years

          -  Pregnant or breastfeeding women

          -  Life expectancy &lt;1 year

          -  Refuse or unwilling to provide consent

          -  Unable to speak English or French
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan R Kahn, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jewish General Hospital (Montreal, Quebec, Canada)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean-Philippe Galanaud, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Susan R Kahn, MD, MSc</last_name>
    <phone>514-340-8222</phone>
    <phone_ext>22790</phone_ext>
    <email>susan.kahn@mcgill.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean-Philippe Galanaud, MD, PhD</last_name>
    <phone>514-340-8222</phone>
    <phone_ext>22790</phone_ext>
    <email>Jean-Philippe.Galanaud@sunnybrook.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sir Mortimer B. Davis - Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Susan R. Kahn, M.D., M.Sc.</last_name>
      <phone>514-340-8222</phone>
      <phone_ext>24667</phone_ext>
    </contact>
    <investigator>
      <last_name>Susan R. Kahn, M.D., M.Sc.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Kahn SR, Pengo V. Special issue: Late consequences of venous thromboembolism. Thromb Res. 2018 Apr;164:99. doi: 10.1016/j.thromres.2018.02.005. Epub 2018 Feb 13.</citation>
    <PMID>29459016</PMID>
  </reference>
  <reference>
    <citation>Rabinovich A, Kahn SR. How I treat the postthrombotic syndrome. Blood. 2018 May 17;131(20):2215-2222. doi: 10.1182/blood-2018-01-785956. Epub 2018 Mar 15. Review.</citation>
    <PMID>29545327</PMID>
  </reference>
  <reference>
    <citation>Kahn SR, Comerota AJ, Cushman M, Evans NS, Ginsberg JS, Goldenberg NA, Gupta DK, Prandoni P, Vedantham S, Walsh ME, Weitz JI; American Heart Association Council on Peripheral Vascular Disease, Council on Clinical Cardiology, and Council on Cardiovascular and Stroke Nursing. The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the American Heart Association. Circulation. 2014 Oct 28;130(18):1636-61. doi: 10.1161/CIR.0000000000000130. Epub 2014 Sep 22. Erratum in: Circulation. 2015 Feb 24;131(8):e359.</citation>
    <PMID>25246013</PMID>
  </reference>
  <reference>
    <citation>Galanaud JP, Monreal M, Kahn SR. Epidemiology of the post-thrombotic syndrome. Thromb Res. 2018 Apr;164:100-109. doi: 10.1016/j.thromres.2017.07.026. Epub 2017 Jul 24. Review.</citation>
    <PMID>28844444</PMID>
  </reference>
  <reference>
    <citation>Cohen JM, Akl EA, Kahn SR. Pharmacologic and compression therapies for postthrombotic syndrome: a systematic review of randomized controlled trials. Chest. 2012 Feb;141(2):308-320. doi: 10.1378/chest.11-1175. Review.</citation>
    <PMID>22315114</PMID>
  </reference>
  <reference>
    <citation>Martinez-Zapata MJ, Vernooij RW, Uriona Tuma SM, Stein AT, Moreno RM, Vargas E, Capell√† D, Bonfill Cosp X. Phlebotonics for venous insufficiency. Cochrane Database Syst Rev. 2016 Apr 6;4:CD003229. doi: 10.1002/14651858.CD003229.pub3. Review.</citation>
    <PMID>27048768</PMID>
  </reference>
  <reference>
    <citation>Bush R, Comerota A, Meissner M, Raffetto JD, Hahn SR, Freeman K. Recommendations for the medical management of chronic venous disease: The role of Micronized Purified Flavanoid Fraction (MPFF). Phlebology. 2017 Apr;32(1_suppl):3-19. doi: 10.1177/0268355517692221. Review. Erratum in: Phlebology. 2017 Dec;32(10 ):NP36.</citation>
    <PMID>28211296</PMID>
  </reference>
  <reference>
    <citation>Rabe E, Agus GB, Roztocil K. Analysis of the effects of micronized purified flavonoid fraction versus placebo on symptoms and quality of life in patients suffering from chronic venous disease: from a prospective randomized trial. Int Angiol. 2015 Oct;34(5):428-36. Epub 2015 May 14.</citation>
    <PMID>25972136</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>January 30, 2019</study_first_submitted>
  <study_first_submitted_qc>February 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2019</study_first_posted>
  <last_update_submitted>July 4, 2019</last_update_submitted>
  <last_update_submitted_qc>July 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sir Mortimer B. Davis - Jewish General Hospital</investigator_affiliation>
    <investigator_full_name>Dr. Susan Kahn</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>deep vein thrombosis</keyword>
  <keyword>chronic venous insufficiency</keyword>
  <keyword>venoactive drug</keyword>
  <keyword>Micronized Purified Flavonoid Fraction</keyword>
  <keyword>DVT</keyword>
  <keyword>post thrombotic syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postthrombotic Syndrome</mesh_term>
    <mesh_term>Postphlebitic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

